While a healthy lifestyle with regular exercise can improve longevity, the key to ageing well is determined by the brain, says a new paper.
Published earlier this month and entitled: ’The Brain Is the Rate-Limiting Organ of Longevity’ it contends that ‘Longevity is not limited by how long the body survives, but by how long the brain can sustain coherent function’.
It says the traditional emphasis on peripheral organ systems, metabolic optimisation, and molecular aging pathways are misplaced.
Authored by Shaheen Lakhan, MD, PhD, founding executive director, at the Miami-based Global Neuroscience Initiative Foundation, he says: “Peripheral organs may determine the final cause of death, but the brain determines the duration and quality of life that precedes it.
“Any longevity strategy that does not explicitly preserve and restore brain function will ultimately fail, regardless of how effectively it slows peripheral aging.
“Recognising the brain as the rate-limiting organ of longevity is therefore not a conceptual preference, but a biological imperative.”
The three ageing benchmarks
Exploring a similar theme, recent Chinese research has identified three ages where substantial brain changes occur.
The first significant change comes at 57, then 70, and then 78, with the researchers identifying biomarkers which indicate these cognitive slumps.
The first change at 57 is due to a reduction in brain volume brought about by a decline in ‘white matter’ – the network of nerve fibres which allows the different brain regions to communicate effectively, they say.
The research measured levels in the brain of 13 proteins that are associated with accelerated brain ageing and neurodegenerative diseases and went on to say that poor lifestyle choices are a key driver of premature decline.
It went to identify exercise as being neuro-protective, by increasing the size of the hippocampus and thereby improving memory.
Alzheimer’s enabler Identified
Researchers at the University of New Mexico have discovered that the enzyme Otulin, known for regulating the immune system, also drives the formation of tau – a protein linked to Alzheimer’s and other neurodegenerative diseases.
In their study, the team demonstrated that deactivating Otulin – either by administering a custom-designed small molecule or knocking out the gene responsible for it – effectively halted tau production and removed the protein from neurons.
The experiments were conducted on two types of cells: one derived from a patient who had died from late-onset sporadic Alzheimer’s disease, and another from a human neuroblastoma cell line often used in neuroscience research.
“Pathological tau is the main player for both brain aging and neurodegenerative disease.
“If you stop tau synthesis by targeting Otulin in neurons, you can restore a healthy brain and prevent brain ageing,” said Dr Karthikeyan Tangavelou, a senior scientist in the department of molecular genetics & microbiology at the UNM School of Medicine.
US$44m for pan-Europe Alzheimer’s attack
A European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management has been launched by the European Commission’s Innovative Health Initiative in Alzheimer’s disease (AD) management,
Over €38m has been secured by the ACCESS-AD consortium – co-led by King’s College London, Amsterdam UMC, Siemens Healthineers and Gates Ventures – for the five year project.
With AD expected to exceed 19 million people in Europe by 2050, ACCESS-AD aims to address the challenges this presents to healthcare systems by ‘accelerating innovation and strengthening equitable access to timely and effective care’.
“By combining technological innovation with economic, ethical, regulatory and patient perspectives, we aim to chart a sustainable, scalable and equitable pathway for the implementation of new AD diagnostics and therapies,” said Prof Dag Aarsland, head of the centre for healthy brain ageing at King’s college London and clinical co-lead of the project
A central focus of the project is the combination of advanced but accessible neuro-imaging with expanded use of fluid and digital biomarkers.
This will support early and accurate patient identification, enabling timely diagnosis and entry into personalised treatment pathways, targeted lifestyle interventions and nutritional strategies.
It’s never too late…
The benefits of regular exercise are highlighted in a 47 year Swedish study on a cohort first enrolled at the age of 16.
Published recently in the Journal of Cachexia, Sarcopenia and Muscle, the study was tasked with seeing how muscles and fitness changed over time in the 427 participants, now aged 63.
The authors found that our bodies start to age from 35, but that the rate of decline can be slowed down if we stay physically active.
The researchers examined the participants’ aerobic capacity, muscular endurance, muscle power and performance in strength training exercises, such as bench press and vertical jump.
The study’s main finding was that peak physical ability arrived before the age of 36, and that after 40, a decline begins, for both sexes.
The researchers found that adults who became physically active later in life improved their performance in the tests by 5 to 10%.
“It is never too late to start moving. Our study shows that physical activity can slow the decline in performance, even if it cannot completely stop it,” said the study’s lead Maria Westerståhl, of the Karolinska Institutet.
